Evaluation of Survival Rate and Pattern of Risk Factors and Recurrence Rate in Patients with Triple-Negative Breast Cancer with other Subtypes

Seyed Mohammad Reza Mortazavizadeh, Nasrollah Bashardoost, Saeed Kargar, Raziyeh Yazdanpanah


Introduction: Breast cancer nowadays is one the major health issue especially in industrial population. Despite excessive researches in this regard, there is still no detailed and relevant information on the association between the risk factors of this cancer and its many outcomes. Due to increasing rate of breast cancer in Iran, including Yazd city, the present study was designed to evaluate the relationship between survival and recurrence rate with pattern of risk factors in breast cancer patients.

Methods: This analytical study was conducted retrospectively on 333 patients with breast cancer during 8 years (2005-2013). Total survival and recurrence rates recorded in month for all samples, and then were analyzed and compared other obtained data. Chi-square and log rank were selected tests for analyzing and Kaplan-Meier was applicable curve for survival analyzing.

Results: The mean age of subjects was 57.02 ± 12.32 years. The mean total survival rate was 93.15 ± 1.25 months (97.9%). The mean total recurrence rate was 84.59 ± 1.91 months (89.8%). The subgroups of breast cancer had no significant relationship with risk factors (P>0.05) though BMI and recurrence rate had significant relationship (P=0.045). Other risk factors had no significant relationship with total survival and recurrence rates. The mean duration of OCP (oral contraceptive pill) consumption was significantly more in the patients with ER-PR-Her2+ subgroup than other groups (P=0.03).  

Conclusion: According the findings, BMI lower than 25 is strong prognostic factor for recurrence rate in patients with triple-negative breast cancer. Because of high survival rate of patients with breast cancer during eight years, it is recommended to study on high survival period with larger sample sizes for accessing reliable evidence. 


Breast cancer, Survival rate, Triple negative

Full Text:



Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U.S.A 2001; 98(19): 10869-74.

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100(18): 10393-8.

Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21): 2492-502.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98(4): 262-72.

Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16(3): 439-43.

Dialla PO, Dabakuyo TS, Marilier S, Gentil J, Roignot P, Darut-Jouve A, et al. Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment. BMC Cancer 2012; 12: 472.

Berrino F, De AR, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8(9): 773-83.

DeVita VT, Lawrence TS, Rosenberg SA. Principles & Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

Huiart L, Bardou VJ, Puig B, Maraninchi D. [Improvement in breast cancer survival between 1975 and 2003 in a cohort of 5722 women]. Bull Cancer 2006; 93(4): 391-9.

Weggelaar I, Aben KK, Warle MC, Strobbe LJ, van Spronsen DJ. Declined guideline adherence in older breast cancer patients: a population-based study in the Netherlands. Breast J 2011; 17(3): 239-45.

Schouten LJ, Hupperets PS, Jager JJ, Volovics L, Wils JA, Verbeek AL, et al. Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res Treat 1997; 43(3): 217-23.

Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M. Parity, age at first childbirth and the prognosis of primary breast cancer. Br J Cancer 1998; 78(11): 1529-33.

Reeves GK, Patterson J, Vessey MP, Yeates D, Jones L. Hormonal and other factors in relation to survival among breast cancer patients. Int J Cancer 2000; 89(3): 293-9.

Rosenberg L, Thalib L, Adami HO, Hall P. Childbirth and breast cancer prognosis. Int J Cancer 2004; 111(5): 772-6.

Black MM, Hankey BF, Barclay TH. Parity as a prognostic factor in young breast cancer patients. J Natl Cancer Inst 1983; 70(1): 27-30.

Mohle-Boetani JC, Grosser S, Whittemore AS, Malec M, Kampert JB, Paffenbarger RS, Jr. Body size, reproductive factors, and breast cancer survival. Prev Med 1988; 17(5): 634-42.

Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 2002; 13(4): 325-32.

Papatestas AE, Mulvihill M, Josi C, Ioannovich J, Lesnick G, Aufses AH, Jr. Parity and prognosis in breast cancer. Cancer 1980; 45(1): 191-4.

Green A, Beral V, Moser K. Mortality in women in relation to their childbearing history. BMJ 1988; 297(6645): 391-5.

Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M. Time since childbirth and prognosis in primary breast cancer: population based study. BMJ 1997; 315(7112): 851-5.

Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL. The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11(3): 235-41.

Ranstam J, Olsson H, Garne JP, Aspegren K, Janzon L. Survival in breast cancer and age at start of oral contraceptive usage. Anticancer Res 1991; 11(6): 2043-6.

Rosner D, Lane WW. Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer 1986; 57(3): 591-6.

Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005; 97(6): 439-48.

Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod 2004; 19(3): 741-56.

Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002; 186(2): 325-34.

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350(9084): 1047-59.

Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O, et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer 1990; 46(4): 597-603.

McDonald PA, Williams R, Dawkins F, Adams-Campbell LL. Breast cancer survival in African American women: is alcohol consumption a prognostic indicator? Cancer Causes Control 2002; 13(6): 543-9.

Holm LE, Nordevang E, Hjalmar ML, Lidbrink E, Callmer E, Nilsson B. Treatment failure and dietary habits in women with breast cancer. J Natl Cancer Inst 1993; 85(1): 32-6.

Yu GP, Ostroff JS, Zhang ZF, Tang J, Schantz SP. Smoking history and cancer patient survival: a hospital cancer registry study. Cancer Detect Prev 1997; 21(6): 497-509.

Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. Cigarette smoking and risk of fatal breast cancer. Am J Epidemiol 1994; 139(10): 1001-7.

Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom). Cancer Causes Control 2001; 12(1): 47-59.

McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 2003; 21(10): 1961-6.

Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998; 47(3): 209-17.

Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 2002; 20(15): 3302-16.


  • There are currently no refbacks.